| Autor: |
Ngô, C., Brugier, C., Plancher, C., de la Rochefordière, A., Alran, S., Féron, J.G., Malhaire, C., Scholl, S., Sastre, X., Rouzier, R., Fourchotte, V. |
| Předmět: |
|
| Zdroj: |
European Journal of Surgical Oncology; Oct2014, Vol. 40 Issue 10, p1237-1244, 8p |
| Abstrakt: |
Objective To compare the clinic-pathologic variables and the prognosis of endometrial cancer in patients with and without previous breast cancer, with and without Tamoxifen. Methods We analyzed patients treated for an endometrial carcinoma from 1994 to 2004: patients without breast cancer (group 1), patients with a previous breast cancer without tamoxifen (group 2) and patients treated for breast cancer with tamoxifen (group 3). Survival rates were calculated according to Kaplan–Meier method and compared using a Log rank test, multivariate analysis was performed with a Cox regression model. Results 363 patients were analyzed. 80 patients had a previous history of breast cancer (43 received tamoxifen). Although it was not statistically significant, more carcinosarcomas were observed in patients in group 3 than patients in groups 1 and 2 (11.7% versus 4.2% and 5.4% respectively, p = 0.17).) Median follow-up was 87 months [2–185]. 5-year overall survival rate was respectively in groups 1, 2 and 3: 82%, 73.2%, and 61% ( p = 0.0006). 5-year local relapse-free survival rate was respectively: 95.9%, 93.1% and 82.5% ( p = 0.02). In multivariate analysis, factors affecting overall survival rate were: age ≥65 ans (HR 3.62, p < 0.0001), FIGO stage (HR 3.33 p < 0.0001 for locally advanced stage versus early stage, HR 8.87 p = 0.03 for distant extension versus early stage), and group 3 (HR 2.83 p < 0.001 versus group 1). Conclusion Patients with endometrial cancer previously treated for breast cancer show a worse prognostic, particularly if they reveived tamoxifen. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect